Drug Ther Bull. 2006 Jan;44(1):5-8. doi: 10.1136/dtb.2006.4415.
Sepsis, the systemic inflammatory response to infection, is common among severely ill patients and can be life-threatening. Over a quarter of patients in UK intensive care units (ICUs) have severe sepsis in the first 24 hours after admission. Of these, 35% die before leaving the ICU and 47% before leaving hospital despite standard therapy. Drotrecogin alfa (activated) (Xigris - Eli Lilly), a recombinant human activated protein C, is licensed for treating adults who have severe sepsis with multiple organ failure. Here we assess its efficacy and safety.
脓毒症是对感染的全身性炎症反应，在重症患者中很常见，且可能危及生命。在英国重症监护病房（ICU）中，超过四分之一的患者在入院后的头24小时内患有严重脓毒症。其中，尽管接受了标准治疗，但35%的患者在离开ICU前死亡，47%的患者在出院前死亡。重组人活化蛋白C活化蛋白C（Xigris - Eli Lilly公司生产）被批准用于治疗患有严重脓毒症并伴有多器官功能衰竭的成年人。在此，我们评估其疗效和安全性。
